What happened
SK biopharmaceuticals filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$132M (+19.2% year on year), operating profit of US$31.5M (+13.8% year on year) and net income of US$90.3M (−28.8% year on year).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$132M |
|---|---|
| Revenue vs a year earlier | +19.2% |
| Operating profit | US$31.5M |
| Net income | US$90.3M |
| Period | Q4 2025 (consolidated) |
| Filed | 2026-02-06, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20260206800127 → open original filing |
Source: DART. Information only, not investment advice.